Aravive Investor Presentation Deck

Batiraxcept + Cabozantinib Phase 1b/2 Trial Design in ccRCC (NCT04300140) Population: 26 patients (P1b) and 55 patients (P2; currently enrolling) # . Histologically confirmed metastatic ccRCC and progressed on/after a front-line treatment regimen Patients previously treated with cabozantinib are excluded P1B Population • 100% of the enrolled patients had prior immunotherapies; -60% had VEGF TKIS Over 70% were in intermediate/poor IMDC categories -40% had more than 1 prior line of therapy Phase 1b AVB-S6-500 Q2W (15 mg/kg N=16) (20 mg/kg N=10) + Cabozantinib 60 mg OD IMDC = International Metastatic RCC Database Consortium (Risk), TKI = tyrosine kinase inhibitor Part A Part B Part C Phase 2 At least 1 prior line of therapy (N=25) AVB-S6-500 15 mg/kg Q2W + Cabozantinib 60 mg QD First line (N=20) AVB-S6-500 15 mg/kg Q2W + Cabozantinib 40 mg QD + Nivolumab (Investigator's Choice): 240 mg Q2W or 480 mg Q4W AVB-S6-500 15 mg/kg Monotherapy in Patients without Curative Intent (N=10) Cabozantinib dosing as indicated on the package insert N

View entire presentation